| Title |
Clinical trials of bestatin for leukemia and solid tumors
|
|---|---|
| Published in |
Biotherapy, March 1992
|
| DOI | 10.1007/bf02174207 |
| Pubmed ID | |
| Authors |
K. Ota, Y. Uzuka |
| Abstract |
A new immunomodulating agent, bestatin (INN: ubenimex) has low toxicity after long-term oral administration and significantly modifies immunological responses. Prolongation of remission duration and survival was achieved in adult acute nonlymphocytic leukemia with bestatin immunotherapy combined with remission maintenance chemotherapy. Patients with myelodysplatic syndrome (MDS) and chronic myelogenous leukemia (CML) responded to bestatin, and it is noted that cytogenetic remission was obtained in CML. MDS and CML are thought to be a family of clonal malignant disorders in which malignant transformations occurs at the level of the pluripotent stem cell. Bestatin may be capable of modifying the biological-proliferative disequilibrium of the disease, and the therapy opens new and promising prospects in the treatment of both MDS and CML. Randomized controlled studies of bestatin immunotherapy were performed in solid tumors including malignant melanoma, carcinoma of the lung, stomach, bladder, head and neck, and esophagus, and therapeutic benefits on disease free-interval or survival were observed in certain types of these cancers. However, the adjuvant activity of bestatin immunotherapy for these cancers should be further investigated to confirm its activity. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 26% |
| Other | 3 | 16% |
| Student > Ph. D. Student | 3 | 16% |
| Student > Doctoral Student | 2 | 11% |
| Student > Bachelor | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 6 | 32% |
| Biochemistry, Genetics and Molecular Biology | 4 | 21% |
| Medicine and Dentistry | 3 | 16% |
| Nursing and Health Professions | 1 | 5% |
| Chemistry | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 4 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2021.
All research outputs
#2,504,472
of 23,106,390 outputs
Outputs from Biotherapy
#5
of 89 outputs
Outputs of similar age
#589
of 18,950 outputs
Outputs of similar age from Biotherapy
#1
of 2 outputs
Altmetric has tracked 23,106,390 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 89 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 18,950 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them